The $100,000 drug that costs $100 to make

Pharma companies are notoriously secretive about their production outlays, especially for blockbuster drugs like sofosbuvir, which is set to radically change the treatment of hepatitis C.

However, a UK study has crunched the numbers, estimating that a 12-week course of this phenomenally expensive antiviral costs its manufacturer Gilead just $100 to make.

Given that a course of the drug - which was recently knocked back by the PBAC for being too expensive - is marketed at $84,000 (A$102,000) in the US, the mark-up is of unprecedented